UnitedHealth Group Draws $1M Fine in NV
Masto said that "although United denies it acquired Fiserv Nevada as prohibited by the judgment, we feel its actions as reflected in internal company documents demonstrate a violation. We are also seeking court approval for Judgment amendments to tighten up its monitoring mechanisms and hence deter possible future non-compliance."
In addition to paying the $1 million fine, UnitedHealth Group agreed to these provisions:
- The fine's proceeds shall be provided to Nevada agencies or charitable organizations dedicated to improving the quality of or access to healthcare in Nevada;
- Payment of attorneys' fees and costs related to investigating the Fiserv Nevada activity (approximately $125,000 as of December 2010);
- Notification of proposed acquisitions by UnitedHealth Group which significantly involve Nevada healthcare markets; and
- Modifications of UnitedHealth Group's internal policies to protect the confidential data belonging to its Nevada-based customers previously with Fiserv Nevada, of which non-compliance can be deemed a judgment violation.
On Monday UnitedHealth Group issued this statement saying it was "pleased" the matter was resolved. "While we disagree with the allegations because UnitedHealth Group did not acquire an interest in, or engage in a joint venture with Fiserv Nevada, we felt it was important to reach a mutual agreement on this issue so we can move forward with our positive working relationship with the Nevada Attorney General's Office and continue to focus our efforts on providing quality service to our Nevada customers."
Margaret Dick Tocknell is a reporter/editor with HealthLeaders Media.
- How Top-Ranked MA Plans Earn Their Stars
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Hospitals Can Become 'Upstreamists'
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- House Calls Key to Pioneer ACO Success
- How Telehealth Pays Off for Providers, Patients
- 4 Tips for Managing Employed Physicians
- Defensive Medicine Still Prevalent Despite Tort Reform
- WellPoint Dominates Nearly Half of Markets, AMA Says
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening